domingo, 8 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 20, 2026

Meta Platforms: From Heavy AI CapEx to 2026 ROI?

View original at finance.yahoo.com
“Reality Labs (home to Meta's VR devices and metaverse projects) generated just over $2.1 billion in revenue but more than $17.7 billion in operating losses”
Verbatim excerpt from the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2025 capital expenditures will exceed $70 billion, approximately 70% higher than in 2024

    80% confidence

  • Time spent on Facebook rose 5% in Q3 2025

    80% confidence

  • Reels is running at a roughly $50 billion annualized revenue rate

    80% confidence

  • Threads usage jumped 10% in Q3 2025

    80% confidence

  • Instagram video consumption is up more than 30% year-over-year

    80% confidence

  • Meta has spent over $40 billion on R&D to date, with a significant portion allocated to AI/ML

    80% confidence

  • 2026 expenses will likely grow at a significantly faster rate than in 2025, largely due to infrastructure and personnel costs as new data center capacity comes online

    80% confidence

  • Lead-gen campaigns using Advantage+ show a 14% lower cost per lead than traditional campaigns

    80% confidence

  • Advantage+ is handling over $60 billion in annual ad spend

    80% confidence

  • Average price per ad rose 10% year-over-year in Q3 2025, credited to AI

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,996
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,996 factos verificados com a fonte5,552 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Meta Platforms: From Heavy AI CapEx to 2026 ROI? — Source | Via News | pt.VIA.NEWS